iXip Literature

14.	Antonelli A, Francavilla S, Gallotta A, Da Pozzo LF, Ferretti S, Sigala S, Simeone C, Mirone V, Artibani W, Porreca A. Actual evidences and future perspectives about the role of iXip® in the diagnosis of prostate cancer: a narrative review.. Minerva Urol Nefrol. . 2019. doi: 10.23736/S0393-2249.19.03329-0
13.	Galosi AB, Dell'Atti L, Bertaccini A, Gion M, Francavilla S, Ferretti S, Maestroni U, Gallotta A, Parrozzani C, Paneghetti L, Fassina G. Clinical evaluation of the iXip index to reduce prostate re-biopsies. Cancer Treat Res Comm. 16:59-63. 2018. doi: 10.1016/j.ctarc.2018.07.001
12.	Gallotta A, Giannarini G, Laurini L, Zani D, Garbeglio A, Guazzieri S, Plebani M, Fassina G, Zattoni F. Clinical validation of the iXip index in avoiding unnecessary prostate biopsy: results from a prospective multicenter study involving 426 patients. Cancer Treat Res Comm. 10:40-45. 2017. doi: 10.1016/j.ctarc.2017.01.002
11.	Tzouvadaki I, Parrozzani C, Gallotta A, De Micheli G, Carrara S. Memristive Biosensors for PSA-IgM Detection. BioNanoSci. 5(4):189-195. 2015. doi: 10.1007/s12668-015-0179-4
10.	Gallotta A, Ziglioli F, Ferretti S, Maestroni U, Moretti M, Aloe R, Gnocchi C, Di Palo M, Fassina G. A novel algorithm for the prediction of prostate cancer in clinically suspected patients. Cancer Biomark. 13(4):227-34. 2013. doi: 10.3233/CBM-130357
9.	Goc S, Jankovic M. Evaluation of Molecular Species of Prostate-Specific Antigen Complexed with Immunoglobulin M in Prostate Cancer and Benign Prostatic Hyperplasia. Dis. Markers. 35(6):847-855. 2013. doi: 10.1155/2013/923819
8.	Giulianelli R, Albanesi L, Brunori S, Gentile B, Mavilla L, Pisanti F, Mirabile G, Shestani T, Attisani F, Schettini M, Damian M, Cervo S, Steffan A. The use of PSA-IgM in the diagnosis of prostate cancer. Urology. 78(S3A):S304. 2011. doi: 10.1016/j.urology.2011.07.948
7.	Prayer-Galetti T, Vianello F, Secco S, Plebani M, Liverani A, Laurini L, Fulcoli V, Lorenzo R, Garbeglio A, Zani D, Cosciani Cunico S, Zattoni F. Il dosaggio dell'immunocomplesso PSA-IgM e la conseguente valutazione dell'indice iXip nella diagnostica del carcinoma prostatico. 84° Congresso SIU. Rome, Italy. 2011.
6.	Verna M, Pengo P, Gallotta A, Zani D, Costa S, Leon A, Gion M, Fassina G, Beneduce L. Improved detection of low grade prostate cancer by PSA-IgM assessment. Anticancer Res. 30:1486-7. 2010.
5.	Zani D, Costa S, Beneduce L, Fassina G, Simeoni C, Cosciani Cunico S. Immunità e cancro: ruolo degli immunocomplessi PSA-IgM nel cancro della prostata. Urologia. 77:1-3. 2010.
4.	Zani D, Costa S, Pettenò A, Simeone C, Cosciani Cunico S, Leon AE, Gion M, Fassina G, Beneduce L. Combined role of serum assays of PSA-IgM and PSA for the diagnosis of prostate cancer. Anticancer Res. 30:1496-7. 2010.
3.	Zani D, Costa S, Gatti L, Pesenti N, Pettenò A, Zambolin T, Simeone C, Cunico S, Leon A, Zuin J, Pengo P, Fassina G, Beneduce L. The association of PSA-IgM and total PSA improves the diagnosis of prostate cancer. Int J Biol Markers. 24:212. 2009.
2.	Beneduce L, Prayer-Galetti T, Giustinian AMG, Gallotta A, Betto G, Pagano F, Fassina G. Detection of prostate-specific antigen coupled to immunoglobulin M in prostate cancer patients. Cancer Detect Prev. 31(5):402-7. 2007.
1.	Beneduce L, Prayer-Galetti T, Marcello Grimani Giustinian A, Gallotta A, Fracalanza S, Betto G, Artibani W, Pagano F. The occurrence of Prostate Specific Antigen-IgM immune complexes (IC) as novel serum biomarker for prostate cancer. Eur Urol Suppl. 5(2):163. 2006. doi: 10.1016/S1569-9056(06)60568-X

Links

	Overview
	Data Sheet
	Product Profile
	Instructions
	Software